PTX-062

**PTX-062** is a preclinical Plecoid oncology candidate from Pleco Therapeutics for **small-cell lung cancer**. It is described as a chemically based chelation-therapy program intended to remove toxic metals from the tumor microenvironment while sparing essential metals, with the goal of improving cancer-cell responsiveness to chemotherapy. The exact active ingredients, dosage form, route of administration, and specific metal targets for PTX-062 have not been publicly disclosed. Pleco Therapeutics lists PTX-062 in its pipeline for small-cell lung cancer. ([plecotherapeutics.com](https://plecotherapeutics.com/pipeline))